Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | FDPS | P14324 | 14/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8623833 | 0.75 | LMNA (0.45) | LMNAFDPSPGK1PGK2CA2 | |
| SCHEMBL10861463 | 0.73 | LMNA (0.43) | LMNAFDPSPGK1PGK2CA2 | |
| SCHEMBL8895794 | 0.71 | LMNA (0.40) | LMNAFDPSTSHRPGK1PGK2 | |
| SCHEMBL2087244 | 0.69 | LMNA (0.45) | LMNAFDPSPGK1PGK2CA2 | |
| SCHEMBL10580976 | 0.69 | LMNA (0.45) | LMNAFDPSPGK1PGK2CA2 | |
| Butanedione SCHEMBL222007 | 0.68 | TSHR (0.64) | LMNATSHRTHPOCA2 | |
| Butanedione SCHEMBL9294413 | 0.65 | TSHR (0.58) | LMNATSHRTHPOCA2 | |
| SCHEMBL134918 | 0.65 | — | — | |
| SCHEMBL4649888 | 0.65 | — | — | |
| SCHEMBL7521130 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173947-B2 | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140329990-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | NEKTAR THERAPEUTICS (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329990-A1 | Hydroxyapatite-Targeting Multiarm Polymers and Conjugates Made Therefrom | CD44, FGF23, PTH1R | LMNA 4075/4885FDPS 3761/4885TSHR 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.